济南快速治阳痿的药济南前列腺肥大什么症状,济南龟头敏感高什么原因造成,济南市男科医院哪个好,济南尿道口分叉,济南那种药治疗早泄比较好,济南手淫过度导致阳痿早泄怎么治疗,济南男科医院咨询

While all hands are on deck to combat the novel coronavirus, there is another virus that experts are keeping their eyes on – the EEE virus, commonly known as the "Triple E."It stands for eastern equine encephalitis.You may have heard of the virus last year when we started seeing more cases outside of Gulf Coast states, where the virus is normally seen."Triple E" can cause inflammation in the brain, which can be deadly.In 2018, the United States only had six cases of "Triple E." In 2019, that number rose to 38, an alarming number considering about a third of people who become infected are expected to die.With coronavirus at top of mind this summer, experts are concerned people may not take the right precautions for "Triple E."“You hear all about coronavirus, having to wear a mask,” said Dr. Brittany Campbell, an entomologist with the National Pest Management Association. “We've been doing social distancing for months now, with a little bit of movement. So, I can understand that everyone is a little bit exhausted from being concerned about their health all of the time. But at this time, I really encourage people to remain diligent.”This can be done by making a habit of dumping out any standing water in your yard and also protecting yourself by wearing repellent.And when it comes to how rampant "Triple E" will be this mosquito season, experts aren't exactly sure. It really depends on the temperature, climate and rain specific to each region.Massachusetts saw a large outbreak last year. The state is now looking at a bill that would have the public health department reduce the mosquito population, as a precaution. 1644

While many think of NASA as the government agency that sends scientists into space, some of NASA’s most important work frequently is used to help people on Earth.In recent months, NASA has used its extensive network of scientists and researchers to combat the coronavirus. And in short order, the agency provided patients and healthcare providers with tools that may have been used to save lives.This week, NASA outlined a number of innovations the agency developed to support the fight against the virus.NASA created an open source for N95 respirators so people can make their own masks by using 3D printers. N95 respirators are unique as they protect the wearer from the virus. NASA’s designs were engineered to meet or exceed standard N95 performance, can be used for different purposes, are compatible with commercially-available filters, and do not disrupt the supply chain.If you have access to a 3D printer, here is how to create an N95 respirator designed by NASA.In addition to NASA’s open-source N95 respirators, the team from Johnson Space Center developed and tested a sterilization protocol to combat a national shortage of N95 masks. This allows N95 respirators to be reused by healthcare providers.“I had a very deep and personal connection to the evaluation (of N95 masks), because my wife is a medical professional… on the frontlines, with only one mask allocated for her to use and re-use daily,” said NASA engineer and project lead Jeremy Jacobs. “She has been very concerned about cross contamination between patient-to-patient and to our family.”Among other innovations, NASA’s Jet Propulsion Laboratory in California designed a new high-pressure ventilator tailored specifically to treat COVID-19 patients. It was designed to treat patients who might not require a full-featured ventilator, keeping the nation’s limited supply of traditional ventilators available, NASA said.NASA’s Armstrong Flight Research Center in California joined several other agencies to create a helmet that functions like a continuous positive airway pressure, commonly known as CPAP, machine to force oxygen into a patient’s low-functioning lungs. 2156

WILMINGTON, Del. — Joe Biden's meeting Thursday with a group of Democratic and Republican governors is his latest attempt to fight through President Donald Trump's unprecedented attempt to block the president-elect's transition to power.Biden and vice president-elect Kamala Harris have planned a virtual session with the National Governors Association's leadership team for Wednesday afternoon, which includes five Republicans and four Democrats.All the Democrats and a majority of the Republicans involved have acknowledged Biden as the winner of the White House election.The president-elect's remarks come as Georgia is slated to release results of a hand recount of the 2020 presidential election in the state. While reports indicate that the tally will include a few more votes for Trump, he will still likely fall far short of overtaking Biden's current lead in the state.Georgia is the only state that the Associated Press has not called for either candidate. Even without Georgia's electoral votes, Biden would still have enough to win the presidency.Trump is continuing to push unsubstantiated claims of voter fraud. On Thursday, he continued to court Republican election officials in Wayne County, Michigan in an attempt to de-certify the results of the heavily Democratic county. 1298

With a coronavirus vaccine still months off, companies are rushing to test what may be the next best thing: drugs that deliver antibodies to fight the virus right away, without having to train the immune system to make them.Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help it be eliminated. Vaccines work by tricking the body into thinking there’s an infection so it makes antibodies and remembers how to do that if the real bug turns up.But it can take a month or two after vaccination or infection for the most effective antibodies to form. The experimental drugs shortcut that process by giving concentrated versions of specific ones that worked best against the coronavirus in lab and animal tests.“A vaccine takes time to work, to force the development of antibodies. But when you give an antibody, you get immediate protection,” said University of North Carolina virologist Dr. Myron Cohen. “If we can generate them in large concentrations, in big vats in an antibody factory ... we can kind of bypass the immune system.”These drugs are believed to last for a month or more and could give quick, temporary immunity to people at high risk of infection, such as health workers and housemates of someone with COVID-19. If they proved effective and if a vaccine doesn’t materialize or protect as hoped, the drugs might eventually be considered for wider use, perhaps for teachers or other groups.They’re also being tested as treatments, to help the immune system and prevent severe symptoms or death.“The hope there is to target people who are in the first week of their illness and that we can treat them with the antibody and prevent them from getting sick,” said Dr. Marshall Lyon, an infectious disease specialist helping to test one such drug at Emory University in Atlanta.Having such a tool “would be a really momentous thing in our fight against COVID,” Cohen said.Vaccines are seen as a key to controlling the virus, which has been confirmed to have infected more than 20 million people worldwide and killed more than 738,000. Several companies are racing to develop vaccines, but the results of the large final tests needed to evaluate them are months away.The antibody drugs are “very promising” and, in contrast, could be available “fairly soon,” said Dr. Janet Woodcock, a U.S. Food and Drug Administration official who is leading government efforts to speed COVID-19 therapies. Key studies are underway and some answers should come by early fall.One company, Eli Lilly, has already started manufacturing its antibody drug, betting that studies now underway will give positive results.“Our goal is to get something out as soon as possible” and to have hundreds of thousands of doses ready by fall, said Lilly’s chief scientific officer, Dr. Daniel Skovronsky.Another company that developed an antibody drug cocktail against Ebola — Regeneron Pharmaceuticals Inc. — now is testing one for coronavirus.“The success with our Ebola program gives us some confidence that we can potentially do this again,” said Christos Kyratsous, a Regeneron microbiologist who helped lead that work.Regeneron’s drug uses two antibodies to enhance chances the drug will work even if the virus evolves to evade action by one.Lilly is testing two different, single-antibody drugs — one with the Canadian company AbCellera and another with a Chinese company, Junshi Biosciences. In July, Junshi said no safety concerns emerged in 40 healthy people who tried it and that larger studies were getting underway.Others working on antibody drugs include Amgen and Adaptive Biotechnologies. The Singapore biotech company Tychan Pte Ltd. also is testing an antibody drug and has similar products in development for Zika virus and yellow fever.“I’m cautiously optimistic” about the drugs, said the nation’s top infectious diseases expert, Dr. Anthony Fauci. “I’m heartened by the experience that we had with Ebola,” where the drugs proved effective.What could go wrong?— The antibodies may not reach all of the places in the body where they need to act, such as deep in the lungs. All the antibody drugs are given through an IV and must make their way through the bloodstream to wherever they’re needed.— The virus might mutate to avoid the antibody — the reason Regeneron is testing a two-antibody combo that binds to the virus in different places to help prevent its escape.Skovronsky said Lilly stuck with one antibody because manufacturing capacity would essentially be cut in half to make two, and “you will have less doses available.” If a single antibody works, “we can treat twice as many people,” he said.— The antibodies might not last long enough. If they fade within a month, it’s still OK for treatment since COVID-19 illness usually resolves in that time. But for prevention, it may not be practical to give infusions more often than every month or two.A San Francisco company, Vir Biotechnology Inc., says it has engineered antibodies to last longer than they usually do to avoid this problem. GlaxoSmithKline has invested 0 million in Vir to test them.Giving a higher dose also may help. If half of antibodies disappear after a month, “if you give twice as much, you will have two months’ protection,” Lilly’s Skovronsky said.— The big fear: Antibodies may do the opposite of what’s hoped and actually enhance the virus’s ability to get into cells or stimulate the immune system in a way that makes people sicker. It’s a theoretical concern that hasn’t been seen in testing so far, but large, definitive experiments are needed to prove safety.“As best as we can tell, the antibodies are helpful,” Lyon said.___Marilynn Marchione can be followed on Twitter: @MMarchioneAP___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 5919

What once was considered a childhood hobby has becoming a way to earn extra income as an adult.The business of trading, buying and selling sports cards is booming.“Cards that used to be worth to are now selling well upwards of 0,” said Mike Fruitman, owner of Mike’s Stadium Sportscards in Aurora, Colorado.He says sports cards are more popular than ever and compares buying the card of an athlete to buying stock in a company.“We had a card that got pulled last night, it featured autographs from R.J. Barrett and Zion Williamson and we anticipate it’s going to be a ,000 card,” Fruitman said.While many businesses are suffering during the pandemic, Fruitman says this industry is seeing some of its biggest sales since the pandemic began, especially once they moved online.“We had a lot of people who were bored who were looking for entertainment,” he said. “We were going online every day during COVID and our viewership was impressive. We were getting views that we never seen before.”Though buying sports cards in person is still profitable, Fruitman says fewer cards are becoming available.“The amount of people who are opening up card stores or becoming breakers, it’s all just taffy,” he said. “And that taffy is just getting slowly apart. Everybody getting less and less it seems.”Card collectors believe the future of this industry depends on part of the popularity.“Right now, you’ve got videos of Mark Wahlberg opening up boxes with his kids,” Fruitman said. “Steve Aoki is a very large, popular DJ, has opened up his own sports card trading store in L.A.”For now, sports cards are combining entertainment and economics with no signs of slowing down.“It depends on how much you can invest,” one collector said. “But yeah, there’s plenty of money to be made.” 1791